STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing
The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers…
Category: Pharma
STAT+: Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds for kids
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: California judge deals GSK a setback as first Zantac lawsuit will now go to trial
In a setback to GSK, a California judge ruled that a consumer cleared a key…
STAT+: Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to deaths
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: J&J loses a patent battle in India over a crucial tuberculosis drug
In a defeat for Johnson & Johnson, the Indian patent office has rejected its bid…
STAT+: Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty med costs
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines
In the face of rising drug prices, health plan sponsors have quietly used a clever,…
Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government
WASHINGTON — Moderna CEO Stéphane Bancel and Senate health committee Chair Bernie Sanders shook hands…
STAT+: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: NIH rejects bid to cut a cancer drug’s price by sidestepping patents
In a long-awaited decision, the U.S. National Institutes of Health rejected a petition urging the…
STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
More than 200 civil society and patient advocacy groups are urging the U.K. government to…
STAT+: Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax breaks in the semiconductor package
Top of the morning to you, and a fine one it is. A bright, shiny…
.jpg)
STAT+: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
WASHINGTON — Moderna CEO Stéphane Bancel has some explaining to do. Bancel will appear alone…
STAT+: Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines
A U.S. lawmaker wants the federal government to probe potential conflicts of interest held by…
STAT+: Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children disappoint
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%
Following the lead of its rivals, Sanofi will cut the price of its most widely…
STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers
U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over…
STAT+: Califf criticizes insurers for doing too little on drug research
WASHINGTON — FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval…
STAT+: Pharmalittle: Alzheimer’s group starts lobbying for Medicare to cover new drug; U.S. judge seems sympathetic to abortion-pill challenge
Good morning, everyone, and how are you today? Hazy skies are enveloping the frosty Pharmalot…
STAT+: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug
In a rare move, a U.K. pharmaceutical industry trade group suspended Novo Nordisk for two…
STAT+: Medicare explains how it will choose drugs for negotiation
WASHINGTON — Medicare laid out Thursday in the greatest detail yet how it will choose…
STAT+: Would the federal government defer to states to regulate PBMs?
WASHINGTON — After years of struggling to regulate the drug middlemen that create pharmacy networks,…
STAT+: Pharmalittle: Biden administration to fine drugmakers for price hikes on 27 meds; Dems push pharmacy chains over access to abortion pill
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Biden administration to fine manufacturers of 27 medicines for price hikes
WASHINGTON — The Biden administration will fine drugmakers who hiked prices faster than the rate…
Opinion: Drug developers navigating ‘biology’s century’ need a model. We made one
STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry…
STAT+: Democratic lawmakers press pharmacy chains on abortion pill access
More than a dozen Democratic lawmakers are urging some of the nation’s largest drugstore chains…
STAT+: PhRMA chief dings health insurers over drug prices at their own conference
WASHINGTON — The head of the brand drug lobby used an in-person health insurance industry…
STAT+: Pharmalittle: Novo to cut some insulin prices by up to 75%; Veterans Administration to cover new Alzheimer’s treatment
Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, in…
STAT+: Novo Nordisk to lower insulin prices by up to 75% amid growing pressure
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products…
STAT+: Veterans Health Administration will cover the newest Alzheimer’s drug
In an unexpected move, the Veterans Health Administration announced Monday that it will widely cover…
STAT+: Pharmalittle: Biogen exec who quarterbacked Aduhelm leaves; Pfizer to buy Seagen for $43 billion
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Sanofi said Monday that it is acquiring Provention Bio, makers of a diabetes treatment, for…
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43…
STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap
And so, another working week will soon draw to a close. Not a moment too…
Opinion: Clearing the patent thicket: A pathway to faster generic drug approvals
Revelations that AbbVie, the manufacturer of Humira, made more than $100 billion in extra profits…
STAT+: Several years later, AstraZeneca says its drug extends life for some early-stage lung cancers
Ever since the Food and Drug Administration approved osimertinib for some early-stage lung cancer patients…
STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices
By law, Medicare will have to take a medication’s efficacy and its research and development…
STAT+: Biden makes drug pricing a central part of his deficit reduction plans
WASHINGTON – President Biden made lowering drug prices a key part of his budget with…
STAT+: Insulin for $20 a vial? Sanders pushes bill for price caps on the diabetes treatment
Now that Eli Lilly is cutting prices on some of its insulin products, U.S. Sen….
STAT+: Pharmalittle: Pharmacies are battlegrounds in the abortion debate; Lilly Alzheimer’s drug failed to prevent memory loss in study
Rise and shine, folks, another busy day is on the way. Already, there was a…
STAT+: An unlikely new 340B alliance emerges between PhRMA and community health centers
WASHINGTON — An unusual new alliance of the brand-drug lobby PhRMA and community health centers…
STAT+: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines
WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive…
STAT+: Pharmalittle: FDA head wants to get rid of advisory panel votes; premature-birth drug is finally withdrawn
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA
After months of anticipation, the manufacturer of a controversial drug for premature births has agreed…
STAT+: Pharmalittle: Biden proposes expanding Medicare drug-price negotiation; Weight Watchers moves into obesity drug market
Top of the morning to you, and a fine one it is. Shiny and clear…
STAT+: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment
A Turkish court overturned a decision by the national antitrust regulator that two years ago…
STAT+: Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links to drug-resistant infections
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Leading ALS advocacy group roiled by infighting over money and priorities
A blistering battle has broken out between the ALS Association and more than a dozen…
STAT+: Teva quits brand lobby PhRMA, in line to lead generic lobby AAM
WASHINGTON — Teva Pharmaceuticals has quit the Pharmaceutical Research and Manufacturers of America, STAT has…